Luuk J J Scheres
Overview
Explore the profile of Luuk J J Scheres including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
228
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scheres L, Middeldorp S
Hematology Am Soc Hematol Educ Program
. 2024 Dec;
2024(1):664-671.
PMID: 39644057
Hormone-related venous thromboembolism (VTE) is common and entails scenarios in which VTE occurs during exposure to exogenous or endogenous female sex hormones, typically estrogen and progestogen. For the management of...
2.
Chen Q, van Rein N, Broeders L, Middeldorp S, Bloemenkamp K, Cannegieter S, et al.
Lancet Haematol
. 2024 Dec;
11(12):e905-e915.
PMID: 39638541
Background: Considering the paucity of data, we aimed to describe nationwide time trends in antithrombotic therapy during pregnancy and risks of maternal and perinatal outcomes in the Netherlands. Methods: In...
3.
Scheres L, Braekkan S, Verlaan J, Cannegieter S, Hansen J, Morelli V
Res Pract Thromb Haemost
. 2024 Jul;
8(4):102447.
PMID: 38953053
Background: For the relationship between obesity and venous thromboembolism (VTE), nonalcoholic fatty liver disease (recently termed metabolic dysfunction-associated steatotic liver disease) is of interest given the hepatic role in hemostasis....
4.
Hamulyak E, Wiegers H, Hutten B, de Lange M, Timmermans A, Westerweel P, et al.
Res Pract Thromb Haemost
. 2024 Jul;
8(4):102448.
PMID: 38953049
No abstract available.
5.
Verlaan J, Stegeman B, Timp J, Scheres L, Flinterman L, Helmerhorst F, et al.
J Thromb Haemost
. 2024 Mar;
22(8):2195-2202.
PMID: 38554933
Background: Extensive evidence is available on hormonal contraceptive (HC) use and the risk of a first venous thromboembolism (VTE) event. Despite recommendations to discontinue combined HC (CHC) use, some women...
6.
Hamulyak E, Westenberg D, Bresser C, Sissing S, Ruiter M, Scheres L, et al.
Thromb Res
. 2023 Jun;
228:200-202.
PMID: 37348321
No abstract available.
7.
Yap E, Lijfering W, Timp J, Rosendaal F, Cannegieter S, Scheres L
EJHaem
. 2023 Feb;
4(1):3-12.
PMID: 36819164
Patients with venous thrombosis (VT) are at increased risk of future arterial cardiovascular disease (CVD) (i.e., myocardial infarction, ischemic stroke or peripheral artery disease). We investigated whether shared risk factors...
8.
Scheres L, van Hylckama Vlieg A, Cannegieter S
Res Pract Thromb Haemost
. 2022 May;
6(4):e12722.
PMID: 35619638
Men seem to have a higher intrinsic risk of venous thromboembolism (VTE) than women, regardless of age. To date, this difference has not been explained. By integrating state-of-the-art research presented...
9.
Scheres L, Middeldorp S, Goddijn M
Hum Reprod
. 2021 Nov;
37(1):190-191.
PMID: 34791264
No abstract available.
10.
Wiegers H, van Es J, Pap A, Lensing A, Middeldorp S, Scheres L
J Thromb Haemost
. 2021 Apr;
19(7):1759-1763.
PMID: 33829647
Background: It is unknown whether differences in clot structure and resolution contribute to the reported risk differences of recurrent venous thromboembolism (VTE) between men and women. Patients/methods: We used data...